NRIX vs. XBI

Last updated Apr 2, 2026

Compare and contrast key facts about Nurix Therapeutics, Inc. (NRIX) and SPDR S&P Biotech ETF (XBI).

XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006.

Performance

NRIX vs. XBI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Nurix Therapeutics, Inc. (NRIX) and SPDR S&P Biotech ETF (XBI). The values are adjusted to include any dividend payments, if applicable.

NRIX vs. XBI - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
NRIX Nurix Therapeutics, Inc.	-18.40%	0.69%	82.56%	-6.01%	-62.07%	-11.95%	72.96%
XBI SPDR S&P Biotech ETF	5.43%	35.89%	1.01%	7.60%	-25.87%	-20.45%	25.68%

Returns By Period

In the year-to-date period, NRIX achieves a -18.40% return, which is significantly lower than XBI's 5.43% return.

NRIX

• 1D: -0.13%
• 1M: -2.09%
• YTD: -18.40%
• 6M: 64.68%
• 1Y: 47.85%
• 3Y*: 20.35%
• 5Y*: -12.98%
• 10Y*: —

XBI

• 1D: 0.64%
• 1M: 1.58%
• YTD: 5.43%
• 6M: 27.21%
• 1Y: 65.07%
• 3Y*: 19.25%
• 5Y*: -1.16%
• 10Y*: 9.39%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NRIX vs. XBI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NRIX

NRIX Risk / Return Rank: 62
NRIX Sharpe Ratio Rank: 65
NRIX Sortino Ratio Rank: 67
NRIX Omega Ratio Rank: 61
NRIX Calmar Ratio Rank: 58
NRIX Martin Ratio Rank: 57

XBI

XBI Risk / Return Rank: 93
XBI Sharpe Ratio Rank: 93
XBI Sortino Ratio Rank: 94
XBI Omega Ratio Rank: 89
XBI Calmar Ratio Rank: 96
XBI Martin Ratio Rank: 95

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NRIX vs. XBI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Nurix Therapeutics, Inc. (NRIX) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NRIX	XBI	Difference
Sharpe ratio Return per unit of total volatility	0.73	2.28	-1.55
Sortino ratio Return per unit of downside risk	1.50	2.99	-1.49
Omega ratio Gain probability vs. loss probability	1.17	1.38	-0.21
Calmar ratio Return relative to maximum drawdown	0.81	4.41	-3.60
Martin ratio Return relative to average drawdown	1.58	16.21	-14.63
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NRIX vs. XBI - Sharpe Ratio Comparison

The current NRIX Sharpe Ratio is 0.73, which is lower than the XBI Sharpe Ratio of 2.28. The chart below compares the historical Sharpe Ratios of NRIX and XBI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NRIX	XBI	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.73	2.28	-1.55
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.17	-0.04	-0.14
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.29	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.04	0.36	-0.40

Correlation

The correlation between NRIX and XBI is 0.62, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

NRIX vs. XBI - Dividend Comparison

NRIX has not paid dividends to shareholders, while XBI's dividend yield for the trailing twelve months is around 0.34%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
NRIX Nurix Therapeutics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
XBI SPDR S&P Biotech ETF	0.34%	0.37%	0.15%	0.02%	0.00%	0.04%	0.20%	0.00%	0.28%	0.24%	0.26%	0.61%

Drawdowns

NRIX vs. XBI - Drawdown Comparison

The maximum NRIX drawdown since its inception was -91.53%, which is greater than XBI's maximum drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for NRIX and XBI.

Drawdown Indicators

	NRIX	XBI	Difference
Max Drawdown Largest peak-to-trough decline	-91.53%	-63.89%	-27.64%
Max Drawdown (1Y) Largest decline over 1 year	-37.48%	-13.39%	-24.09%
Max Drawdown (5Y) Largest decline over 5 years	-88.42%	-55.04%	-33.38%
Max Drawdown (10Y) Largest decline over 10 years	—	-63.89%	—
Current Drawdown Current decline from peak	-69.14%	-25.70%	-43.44%
Average Drawdown Average peak-to-trough decline	-61.41%	-20.91%	-40.50%
Ulcer Index Depth and duration of drawdowns from previous peaks	19.17%	3.65%	+15.52%

Volatility

NRIX vs. XBI - Volatility Comparison

Nurix Therapeutics, Inc. (NRIX) has a higher volatility of 15.09% compared to SPDR S&P Biotech ETF (XBI) at 11.31%. This indicates that NRIX's price experiences larger fluctuations and is considered to be riskier than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NRIX	XBI	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.09%	11.31%	+3.78%
Volatility (6M) Calculated over the trailing 6-month period	46.83%	19.25%	+27.58%
Volatility (1Y) Calculated over the trailing 1-year period	67.01%	28.95%	+38.06%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	74.55%	32.23%	+42.32%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	80.75%	32.15%	+48.60%